Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summit

October 14, 2009 9:00 AM EDT

HAIFA, Israel--(BUSINESS WIRE)-- Pluristem Therapeutics Inc. (NasdaqCM: PSTI)(DAX:PJT) today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

"Selecting Pluristem to present at this conference is a recognition of our innovative technology and its potential to treat several severe ischemic and autoimmune disorders," said Mr. Aberman. "Our ongoing clinical trials in the U.S. and Europe in patients with critical limb ischemia combined with our proprietary technology, position Pluristem as one of the leading companies in the cell therapy field, not only in Israel but also globally."

The New England-Israel Life Sciences Summit will feature 15 Israeli life sciences companies that offer cutting edge technologies in the pharmaceuticals, biotechnology, medical devices and healthcare IT industries. The keynote speaker at the summit will be Mr. Israel Makov, Chairman, Given Imaging and former CEO of Teva Pharmaceutical Industries Ltd. Mr. Deval Patrick, the Honorable Governor of Massachusetts, will be the featured speaker.

About Pluristem

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that our selection to present at the New England-Israel Life Sciences Summit is a recognition of our innovative technology and its potential to treat several severe ischemic and autoimmune disorders, or that our ongoing clinical trials in the U.S. and Europe in patients with critical limb ischemia combined with our proprietary technology, position Pluristem as one of the leading companies in the cell therapy field, not only in Israel but also globally, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

    Source: Pluristem Therapeutics Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?